(VIANEWS) – The NASDAQ opens in less than one hour and ImmunoGen‘s pre-market value is already 6.86% up.
ImmunoGen’s last close was $4.35, 34.39% under its 52-week high of $6.63.
The last session, NASDAQ finished with ImmunoGen (IMGN) sliding 0% to $4.35. NASDAQ jumped 1.48% to $11,891.79, following the last session’s upward trend on what was an all-around up trend exchanging session.
About ImmunoGen
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.252.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -100.96%.
More news about ImmunoGen (IMGN).
